Evidence map›Paper›PMID 36183161›Full record

ArticleThe American journal of case reports2022

Cryptococcus neoformans Presenting as a Lung Mass in an Immunocompromised Patient.

Siddique Qurashi, Tabinda Saleem, Iuliia Kovalenko, Konstantin Golubykh, Lauren Holleran

Open access · hybridAbstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Siddique QurashiDepartment of Internal Medicine, University of Pittsburgh Medical Center (UPMC), Harrisburg, PA, USA.
Tabinda SaleemDepartment of Internal Medicine, University of Pittsburgh Medical Center (UPMC), Harrisburg, PA, USA.
Iuliia KovalenkoDepartment of Internal Medicine, University of Pittsburgh Medical Center (UPMC), Harrisburg, PA, USA.
Konstantin GolubykhDepartment of Internal Medicine, University of Pittsburgh Medical Center (UPMC), Harrisburg, PA, USA.ORCID 0000-0002-4093-4639
Lauren HolleranDepartment of Internal Medicine, Drexel University, Philadelphia, PA, USA.
University of Pittsburgh Medical Center · USDrexel University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Pulmonary cryptococcosis is an uncommon infection mainly affecting immunocompromised individuals. Presentation of cryptococcal disease ranges from asymptomatic pulmonary colonization to severe pneumonia. It can progress to acute respiratory failure and life-threatening meningoencephalitis. CASE REPORT A 55-year-old woman with a history of a kidney transplant, on immunosuppressive therapy, presented to the hospital with persistent low-grade fever, headache, weight loss, and fatigue for 2 weeks. On arrival, she was tachycardic, normotensive, and saturating 99% on room air. Her chest X-ray showed right middle lung opacity measuring 1.9×2.8 cm. She was admitted and started on broad-spectrum antibiotics for suspected pneumonia. Her chest computed tomography (CT) scan showed a 3.0×1.7 cm hypo-dense opacity at the right upper lobe. Overnight, she developed a severe headache and neck stiffness. Her serum cryptococcal antigen and cerebrospinal fluid culture results were positive. The patient was started on intravenous liposomal amphotericin B plus flucytosine. A CT-guided lung biopsy was performed to rule out malignancy. Cultures came back positive for Cryptococcus neoformans. She completed a 2-week course of amphotericin and flucytosine and was switched to oral fluconazole to complete an 8-week course. CONCLUSIONS Prompt diagnosis and effective management of the cryptococcal disease can decrease morbidity and mortality. Diagnosis requires CT-guided lung biopsy, with culture growing mucoid colonies of Cryptococcus neoformans. Antifungal therapy with intravenous liposomal amphotericin B plus flucytosine is the mainstay of treatment. Clinicians should be aware of the various presentations of pulmonary cryptococcosis, especially in immunocompromised patients.

Indexed as

CryptococcosisCryptococcus neoformansAmphotericin BAnti-Bacterial AgentsAntifungal AgentsFemaleFluconazoleFlucytosineHeadacheHumansImmunocompromised HostLungMiddle AgedAmphotericin BAnti-Bacterial AgentsAntifungal AgentsFluconazoleFlucytosineliposomal amphotericin B

Identifiers

PMID36183161
PMCPMC9536145
OpenAlexW4294686882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.